Antonio Oliver

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2072871/publications.pdf

Version: 2024-02-01

322 papers	21,252 citations	9786 73 h-index	14208 128 g-index
351 all docs	351 docs citations	351 times ranked	19882 citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet, The, 2020, 396, 535-544.	13.7	1,465
2	High Frequency of Hypermutable <i>Pseudomonas aeruginosa</i> in Cystic Fibrosis Lung Infection. Science, 2000, 288, 1251-1253.	12.6	1,322
3	Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clinical Microbiology Reviews, 2019, 32, .	13.6	489
4	The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resistance Updates, 2015, 21-22, 41-59.	14.4	475
5	Antimicrobial susceptibility testing in biofilm-growing bacteria. Clinical Microbiology and Infection, 2014, 20, 981-990.	6.0	391
6	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 726-734.	9.1	367
7	Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. Nature, 2021, 595, 707-712.	27.8	363
8	Community Infections Caused by Extended-Spectrum Î²-Lactamaseâ€“Producing Escherichia coli. Archives of Internal Medicine, 2008, 168, 1897.	3.8	333
9	Antibiotic treatment of biofilm infections. Apmis, 2017, 125, 304-319.	2.0	299
10	Communityâ€Onset Bacteremia Due to Extendedâ€Spectrum Î²â€Lactamaseâ€“Producing<i>Escherichia coli:</i>Risk Factors and Prognosis. Clinical Infectious Diseases, 2010, 50, 40-48.	5.8	294
11	Hypermutation Is a Key Factor in Development of Multiple-Antimicrobial Resistance in Pseudomonas aeruginosa Strains Causing Chronic Lung Infections. Antimicrobial Agents and Chemotherapy, 2005, 49, 3382-3386.	3.2	274
12	Coevolution with viruses drives the evolution of bacterial mutation rates. Nature, 2007, 450, 1079-1081.	27.8	263
13	Î²-Lactam Resistance Response Triggered by Inactivation of a Nonessential Penicillin-Binding Protein. PLoS Pathogens, 2009, 5, e1000353.	4.7	258
14	The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Molecular Microbiology, 2002, 43, 1641-1650.	2.5	243
15	Chronic<i>Pseudomonas aeruginosa</i>Infection in Chronic Obstructive Pulmonary Disease. Clinical Infectious Diseases, 2008, 47, 1526-1533.	5.8	235
16	OXA-24, a Novel Class D Î²-Lactamase with Carbapenemase Activity in an <i>Acinetobacter baumannii</i> Clinical Strain. Antimicrobial Agents and Chemotherapy, 2000, 44, 1556-1561.	3.2	226
17	Genetic Adaptation of <i>Pseudomonas aeruginosa</i> to the Airways of Cystic Fibrosis Patients Is Catalyzed by Hypermutation. Journal of Bacteriology, 2008, 190, 7910-7917.	2.2	219
18	Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC. Antimicrobial Agents and Chemotherapy, 2014, 58, 3091-3099.	3.2	197

#	ARTICLE	IF	CITATIONS
19	Genetic Markers of Widespread Extensively Drug-Resistant Pseudomonas aeruginosa High-Risk Clones. Antimicrobial Agents and Chemotherapy, 2012, 56, 6349-6357.	3.2	189
20	The Versatile Mutational Resistome of Pseudomonas aeruginosa. Frontiers in Microbiology, 2018, 9, 685.	3.5	181
21	Genes Encoding TEM-4, SHV-2, and CTX-M-10 Extended-Spectrum Î²-Lactamases Are Carried by Multiple<i>Klebsiella pneumoniae</i>Clones in a Single Hospital (Madrid, 1989 to 2000). Antimicrobial Agents and Chemotherapy, 2002, 46, 500-510.	3.2	178
22	Characterization of Clinical Isolates of<i>Klebsiella pneumoniae</i>from 19 Laboratories Using the National Committee for Clinical Laboratory Standards Extended-Spectrum Î²-Lactamase Detection Methods. Journal of Clinical Microbiology, 2001, 39, 2864-2872.	3.9	170
23	Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates. Antimicrobial Agents and Chemotherapy, 2016, 60, 1767-1778.	3.2	170
24	Overexpression of AmpC and Efflux Pumps in Pseudomonas aeruginosa Isolates from Bloodstream Infections: Prevalence and Impact on Resistance in a Spanish Multicenter Study. Antimicrobial Agents and Chemotherapy, 2011, 55, 1906-1911.	3.2	168
25	Stepwise Upregulation of the Pseudomonas aeruginosa Chromosomal Cephalosporinase Conferring High-Level Î²-Lactam Resistance Involves Three AmpD Homologues. Antimicrobial Agents and Chemotherapy, 2006, 50, 1780-1787.	3.2	164
26	Extended-spectrum Î²-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. International Journal of Antimicrobial Agents, 2009, 34, 173-176.	2.5	164
27	Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance. Clinical Microbiology and Infection, 2010, 16, 798-808.	6.0	162
28	Molecular Epidemiology and Mechanisms of Carbapenem Resistance in <i>Pseudomonas aeruginosa</i> Isolates from Spanish Hospitals. Antimicrobial Agents and Chemotherapy, 2007, 51, 4329-4335.	3.2	161
29	Outbreak of a Multiresistant Klebsiella pneumoniae Strain in an Intensive Care Unit: Antibiotic Use as Risk Factor for Colonization and Infection. Clinical Infectious Diseases, 2000, 30, 55-60.	5.8	160
30	Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2018, 73, 658-663.	3.0	157
31	Influence of Virulence Genotype and Resistance Profile in the Mortality of Pseudomonas aeruginosa Bloodstream Infections. Clinical Infectious Diseases, 2015, 60, 539-548.	5.8	153
32	Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired Î²-lactamases: 2020 update. International Journal of Antimicrobial Agents, 2020, 56, 106196.	2.5	147
33	Molecular Mechanisms of Î²-Lactam Resistance Mediated by AmpC Hyperproduction in Pseudomonas aeruginosa Clinical Strains. Antimicrobial Agents and Chemotherapy, 2005, 49, 4733-4738.	3.2	146
34	Risk Factors and Prognosis of Nosocomial Bloodstream Infections Caused by Extended-Spectrum-Î²-Lactamase-Producing <i>Escherichia coli</i>. Journal of Clinical Microbiology, 2010, 48, 1726-1731.	3.9	144
35	Hypermutation and the Preexistence of Antibiotic-Resistant Pseudomonas aeruginosa Mutants: Implications for Susceptibility Testing and Treatment of Chronic Infections. Antimicrobial Agents and Chemotherapy, 2004, 48, 4226-4233.	3.2	138
36	Pan-Î²-Lactam Resistance Development in Pseudomonas aeruginosa Clinical Strains: Molecular Mechanisms, Penicillin-Binding Protein Profiles, and Binding Affinities. Antimicrobial Agents and Chemotherapy, 2012, 56, 4771-4778.	3.2	138

#	Article	IF	Citations
37	A Multinational, Preregistered Cohort Study of Î²-Lactam/Î²-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-Î²-Lactamase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2016, 60, 4159-4169.	3.2	137
38	Effect of Adequate Single-Drug vs Combination Antimicrobial Therapy on Mortality in Pseudomonas aeruginosa Bloodstream Infections: A Post Hoc Analysis of a Prospective Cohort. Clinical Infectious Diseases, 2013, 57, 208-216.	5.8	135
39	Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clinical Microbiology and Infection, 2005, 11, 690-703.	6.0	134
40	Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. Journal of Antimicrobial Chemotherapy, 2011, 66, 2022-2027.	3.0	132
41	Prospective Multicenter Study of Carbapenemase-Producing Enterobacteriaceae from 83 Hospitals in Spain Reveals High <i>In Vitro</i> Susceptibility to Colistin and Meropenem. Antimicrobial Agents and Chemotherapy, 2015, 59, 3406-3412.	3.2	130
42	Characterization of a Large Outbreak by CTX-M-1-Producing Klebsiella pneumoniae and Mechanisms Leading to In Vivo Carbapenem Resistance Development. Journal of Clinical Microbiology, 2006, 44, 2831-2837.	3.9	126
43	Inactivation of the hmgA gene of Pseudomonas aeruginosa leads to pyomelanin hyperproduction, stress resistance and increased persistence in chronic lung infection. Microbiology (United Kingdom), 2009, 155, 1050-1057.	1.8	124
44	Prospective Multicenter Study of the Impact of Carbapenem Resistance on Mortality in Pseudomonas aeruginosa Bloodstream Infections. Antimicrobial Agents and Chemotherapy, 2012, 56, 1265-1272.	3.2	123
45	Epidemiology of Extended-Spectrum Â-Lactamase-Producing Enterobacter Isolates in a Spanish Hospital during a 12-Year Period. Journal of Clinical Microbiology, 2002, 40, 1237-1243.	3.9	119
46	Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone. Scientific Reports, 2017, 7, 5555.	3.3	117
47	Host and Pathogen Biomarkers for Severe Pseudomonas aeruginosa Infections. Journal of Infectious Diseases, 2017, 215, S44-S51.	4.0	116
48	Analysis of steroid 21-hydroxylase gene mutations in the Spanish population. Human Genetics, 1995, 96, 198-204.	3.8	112
49	Alterations of OprD in Carbapenem-Intermediate and -Susceptible Strains of Pseudomonas aeruginosa Isolated from Patients with Bacteremia in a Spanish Multicenter Study. Antimicrobial Agents and Chemotherapy, 2012, 56, 1703-1713.	3.2	111
50	Predicting antimicrobial resistance in <i>Pseudomonas aeruginosa</i> with machine learningâ€enabled molecular diagnostics. EMBO Molecular Medicine, 2020, 12, e10264.	6.9	111
51	Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	108
52	Nucleotide Sequence and Characterization of a Novel Cefotaxime-Hydrolyzing Î²-Lactamase (CTX-M-10) Isolated in Spain. Antimicrobial Agents and Chemotherapy, 2001, 45, 616-620.	3.2	106
53	Metallo-Â-lactamase-producing Pseudomonas putida as a reservoir of multidrug resistance elements that can be transferred to successful Pseudomonas aeruginosa clones. Journal of Antimicrobial Chemotherapy, 2010, 65, 474-478.	3.0	105
54	Biological Markers of Pseudomonas aeruginosa Epidemic High-Risk Clones. Antimicrobial Agents and Chemotherapy, 2013, 57, 5527-5535.	3.2	104

#	Article	IF	Citations
55	Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing. Antimicrobial Agents and Chemotherapy, 2016, 60, 7415-7423.	3.2	99
56	PBP3 inhibition elicits adaptive responses in Pseudomonas aeruginosa. Molecular Microbiology, 2006, 62, 84-99.	2.5	97
57	Activity of a New Cephalosporin, CXA-101 (FR264205), against Î²-Lactam-Resistant <i>Pseudomonas aeruginosa</i> Mutants Selected <i>In Vitro</i> and after Antipseudomonal Treatment of Intensive Care Unit Patients. Antimicrobial Agents and Chemotherapy, 2010, 54, 1213-1217.	3.2	96
58	<i>Pseudomonas aeruginosa</i> RsmA Plays an Important Role during Murine Infection by Influencing Colonization, Virulence, Persistence, and Pulmonary Inflammation. Infection and Immunity, 2008, 76, 632-638.	2.2	92
59	WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent â€œÎ²-Lactam Enhancerâ€• Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-Î²-Lactamase-Producing High-Risk Clones. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	92
60	Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology. Journal of Antimicrobial Chemotherapy, 2019, 74, 1825-1835.	3.0	92
61	Benefit of Having Multiple<i>ampD</i>Genes for Acquiring Î²-Lactam Resistance without Losing Fitness and Virulence in<i>Pseudomonas aeruginosa</i>. Antimicrobial Agents and Chemotherapy, 2008, 52, 3694-3700.	3.2	91
62	Nosocomial Spread of Colistin-Only-Sensitive Sequence Type 235 <i>Pseudomonas aeruginosa</i> Isolates Producing the Extended-Spectrum Î²-Lactamases GES-1 and GES-5 in Spain. Antimicrobial Agents and Chemotherapy, 2009, 53, 4930-4933.	3.2	91
63	Prevalence and molecular epidemiology of acquired AmpC Î²-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 253-259.	2.9	91
64	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Mayo Clinic Proceedings, 2016, 91, 1362-1371.	3.0	89
65	Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of <i>Pseudomonas aeruginosa</i>. Antimicrobial Agents and Chemotherapy, 2010, 54, 3933-3937.	3.2	88
66	Biological cost of hypermutation in Pseudomonas aeruginosa strains from patients with cystic fibrosis. Microbiology (United Kingdom), 2007, 153, 1445-1454.	1.8	85
67	Activity of a New Antipseudomonal Cephalosporin, CXA-101 (FR264205), against Carbapenem-Resistant and Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Clinical Strains. Antimicrobial Agents and Chemotherapy, 2010, 54, 846-851.	3.2	85
68	Nontuberculous Mycobacteria in Patients with Cystic Fibrosis. Clinical Infectious Diseases, 2001, 32, 1298-1303.	5.8	83
69	Diversity and regulation of intrinsic Î²-lactamases from non-fermenting and other Gram-negative opportunistic pathogens. FEMS Microbiology Reviews, 2017, 41, 781-815.	8.6	83
70	Mechanisms of Decreased Susceptibility to Cefpodoxime in Escherichia coli. Antimicrobial Agents and Chemotherapy, 2002, 46, 3829-3836.	3.2	79
71	Mutators in cystic fibrosis chronic lung infection: Prevalence, mechanisms, and consequences for antimicrobial therapy. International Journal of Medical Microbiology, 2010, 300, 563-572.	3.6	79
72	Structure and interaction with phospholipids of a prokaryotic lipoxygenase from <i>Pseudomonas aeruginosa</i>. FASEB Journal, 2013, 27, 4811-4821.	0.5	78

#	Article	IF	Citations
73	Efficacy and Potential for Resistance Selection of Antipseudomonal Treatments in a Mouse Model of Lung Infection by Hypermutable Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2006, 50, 975-983.	3.2	77
74	Wide Dispersion of ST175 Clone despite High Genetic Diversity of Carbapenem-Nonsusceptible Pseudomonas aeruginosa Clinical Strains in 16 Spanish Hospitals. Journal of Clinical Microbiology, 2011, 49, 2905-2910.	3.9	76
75	Two Mechanisms of Killing of Pseudomonas aeruginosa by Tobramycin Assessed at Multiple Inocula via Mechanism-Based Modeling. Antimicrobial Agents and Chemotherapy, 2015, 59, 2315-2327.	3.2	76
76	Role of Pseudomonas aeruginosa Low-Molecular-Mass Penicillin-Binding Proteins in AmpC Expression, Î²-Lactam Resistance, and Peptidoglycan Structure. Antimicrobial Agents and Chemotherapy, 2015, 59, 3925-3934.	3.2	75
77	Azithromycin in <i>Pseudomonas aeruginosa</i> Biofilms: Bactericidal Activity and Selection of <i>nfxB</i> Mutants. Antimicrobial Agents and Chemotherapy, 2009, 53, 1552-1560.	3.2	73
78	Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain. Journal of Infection, 2016, 72, 152-160.	3.3	73
79	Chronic colonization by Pseudomonas aeruginosa of patients with obstructive lung diseases: cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. Diagnostic Microbiology and Infectious Disease, 2010, 68, 20-27.	1.8	72
80	Determining Î²-lactam exposure threshold to suppress resistance development in Gram-negative bacteria. Journal of Antimicrobial Chemotherapy, 2017, 72, 1421-1428.	3.0	72
81	Characterization of the New Metallo-Î²-Lactamase VIM-13 and Its Integron-Borne Gene from a <i>Pseudomonas aeruginosa</i> Clinical Isolate in Spain. Antimicrobial Agents and Chemotherapy, 2008, 52, 3589-3596.	3.2	71
82	CTX-M-10 Linked to a Phage-Related Element Is Widely Disseminated among Enterobacteriaceae in a Spanish Hospital. Antimicrobial Agents and Chemotherapy, 2005, 49, 1567-1571.	3.2	70
83	High Î²-Lactamase Levels Change the Pharmacodynamics of Î²-Lactam Antibiotics in Pseudomonas aeruginosa Biofilms. Antimicrobial Agents and Chemotherapy, 2013, 57, 196-204.	3.2	69
84	Clonal Dissemination, Emergence of Mutator Lineages and Antibiotic Resistance Evolution in Pseudomonas aeruginosa Cystic Fibrosis Chronic Lung Infection. PLoS ONE, 2013, 8, e71001.	2.5	69
85	Inappropriate use of antibiotics in hospitals: The complex relationship between antibiotic use and antimicrobial resistance. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 3-11.	0.5	68
86	Characterization of plasmids encoding blaESBL and surrounding genes in Spanish clinical isolates of Escherichia coli and Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2008, 63, 60-66.	3.0	66
87	Inactivation of the Glycoside Hydrolase NagZ Attenuates Antipseudomonal Î²-Lactam Resistance in <i>Pseudomonas aeruginosa</i>. Antimicrobial Agents and Chemotherapy, 2009, 53, 2274-2282.	3.2	65
88	Detection and Susceptibility Testing of Hypermutable Pseudomonas aeruginosa Strains with the Etest and Disk Diffusion. Antimicrobial Agents and Chemotherapy, 2004, 48, 2665-2672.	3.2	64
89	Using the Electronic Nose to Identify Airway Infection during COPD Exacerbations. PLoS ONE, 2015, 10, e0135199.	2.5	62
90	Impact of AmpC Derepression on Fitness and Virulence: the Mechanism or the Pathway?. MBio, 2016, 7, .	4.1	62

#	ARTICLE	IF	CITATIONS
91	NagZ Inactivation Prevents and Reverts Î²-Lactam Resistance, Driven by AmpD and PBP 4 Mutations, in <i>Pseudomonas aeruginosa</i>. Antimicrobial Agents and Chemotherapy, 2010, 54, 3557-3563.	3.2	61
92	Providing Î²-lactams a helping hand: targeting the AmpC Î²-lactamase induction pathway. Future Microbiology, 2011, 6, 1415-1427.	2.0	61
93	Intrinsic and Environmental Mutagenesis Drive Diversification and Persistence of Pseudomonas aeruginosa in Chronic Lung Infections. Journal of Infectious Diseases, 2012, 205, 121-127.	4.0	61
94	<i>In Vivo</i> Emergence of Resistance to Novel Cephalosporinâ€“Î²-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 Î²-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	61
95	Lack of Association between Hypermutation and Antibiotic Resistance Development in Pseudomonas aeruginosa Isolates from Intensive Care Unit Patients. Antimicrobial Agents and Chemotherapy, 2004, 48, 3573-3575.	3.2	60
96	Dynamics of Mutator and Antibiotic-Resistant Populations in a Pharmacokinetic/Pharmacodynamic Model of Pseudomonas aeruginosa Biofilm Treatment. Antimicrobial Agents and Chemotherapy, 2011, 55, 5230-5237.	3.2	60
97	Evaluation of the NCCLS Extended-Spectrum Î²-Lactamase Confirmation Methods for<i>Escherichia coli</i>with Isolates Collected during Project ICARE. Journal of Clinical Microbiology, 2003, 41, 3142-3146.	3.9	59
98	VIM-2â€“producing Multidrug-Resistant<i>Pseudomonas aeruginosa</i>ST175 Clone, Spain. Emerging Infectious Diseases, 2012, 18, 1235-41.	4.3	59
99	Antagonistic Interactions of Pseudomonas aeruginosa Antibiotic Resistance Mechanisms in Planktonic but Not Biofilm Growth. Antimicrobial Agents and Chemotherapy, 2011, 55, 4560-4568.	3.2	58
100	Mutation and Evolution of Antibiotic Resistance: Antibiotics as Promoters of Antibiotic Resistance?. Current Drug Targets, 2002, 3, 345-349.	2.1	57
101	Potent Î²-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	57
102	The Pseudomonas aeruginosa CreBC Two-Component System Plays a Major Role in the Response to Î²-Lactams, Fitness, Biofilm Growth, and Global Regulation. Antimicrobial Agents and Chemotherapy, 2014, 58, 5084-5095.	3.2	56
103	Environmental Microbiota Represents a Natural Reservoir for Dissemination of Clinically Relevant Metallo-Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2011, 55, 5376-5379.	3.2	55
104	A large sustained endemic outbreak of multiresistant Pseudomonas aeruginosa: a new epidemiological scenario for nosocomial acquisition. BMC Infectious Diseases, 2011, 11, 272.	2.9	54
105	Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic Î²-Lactam-Resistant Mutants. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	54
106	In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens. Scientific Reports, 2020, 10, 7163.	3.3	54
107	Evolution and Adaptation in Pseudomonas aeruginosa Biofilms Driven by Mismatch Repair System-Deficient Mutators. PLoS ONE, 2011, 6, e27842.	2.5	53
108	Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 2191-2200.	2.9	53

#	Article	IF	Citations
109	Regulation of AmpC-Driven Î²-Lactam Resistance in Pseudomonas aeruginosa: Different Pathways, Different Signaling. MSystems, 2019, 4, .	3.8	53
110	Panbioâ„¢ rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care. Journal of Infection, 2021, 82, 391-398.	3.3	53
111	Novel Phosphorylcholineâ€Containing Protein of<i>Pseudomonas aeruginosa</i>Chronic Infection Isolates Interacts with Airway Epithelial Cells. Journal of Infectious Diseases, 2008, 197, 465-473.	4.0	52
112	Molecular Characterization of FOX-4, a New AmpC-Type Plasmid-Mediated Î²-Lactamase from an Escherichia coli Strain Isolated in Spain. Antimicrobial Agents and Chemotherapy, 2000, 44, 2549-2553.	3.2	50
113	A Standard Numbering Scheme for Class C Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	50
114	Minimum information guideline for spectrophotometric and fluorometric methods to assess biofilm formation in microplates. Biofilm, 2020, 2, 100010.	3.8	50
115	Spanish Multicenter Study of the Epidemiology and Mechanisms of Amoxicillin-Clavulanate Resistance in Escherichia coli. Antimicrobial Agents and Chemotherapy, 2012, 56, 3576-3581.	3.2	49
116	The problems of antibiotic resistance in cystic fibrosis and solutions. Expert Review of Respiratory Medicine, 2015, 9, 73-88.	2.5	49
117	Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing <i>Escherichia coli</i> and ESBL-Producing <i>Klebsiella pneumoniae</i>. Infection Control and Hospital Epidemiology, 2018, 39, 660-667.	1.8	49
118	Inactivation of the Mismatch Repair System in Pseudomonas aeruginosa Attenuates Virulence but Favors Persistence of Oropharyngeal Colonization in Cystic Fibrosis Mice. Journal of Bacteriology, 2007, 189, 3665-3668.	2.2	48
119	<i>ampG</i> Gene of <i>Pseudomonas aeruginosa</i> and Its Role in Î²-Lactamase Expression. Antimicrobial Agents and Chemotherapy, 2010, 54, 4772-4779.	3.2	48
120	Evaluation of the Wider System, a New Computer-Assisted Image-Processing Device for Bacterial Identification and Susceptibility Testing. Journal of Clinical Microbiology, 2000, 38, 1339-1346.	3.9	48
121	Characterization of the GO system ofPseudomonas aeruginosa. FEMS Microbiology Letters, 2002, 217, 31-35.	1.8	47
122	AmpG Inactivation Restores Susceptibility of Pan-Î²-Lactam-Resistant Pseudomonas aeruginosa Clinical Strains. Antimicrobial Agents and Chemotherapy, 2011, 55, 1990-1996.	3.2	47
123	Transferable Multidrug Resistance Plasmid Carrying <i>cfr</i> Associated with <i>tet</i> (L), <i>ant(4</i> â€² <i>)-Ia</i> , and <i>dfrK</i> Genes from a Clinical Methicillin-Resistant Staphylococcus aureus ST125 Strain. Antimicrobial Agents and Chemotherapy, 2012, 56, 2139-2142.	3.2	47
124	Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant Î²-Lactam Resistance Mechanisms. Antimicrobial Agents and Chemotherapy, 2016, 60, 6407-6410.	3.2	47
125	Rapid evolution and host immunity drive the rise and fall of carbapenem resistance during an acute Pseudomonas aeruginosa infection. Nature Communications, 2021, 12, 2460.	12.8	47
126	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-Î²-lactamase-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw513.	3.0	46

#	ARTICLE	IF	CITATIONS
127	Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC Î²-lactamases. Journal of Infection, 2012, 64, 176-183.	3.3	45
128	Molecular Epidemiology and Multidrug Resistance Mechanisms of <i>Pseudomonas aeruginosa</i> Isolates from Bulgarian Hospitals. Microbial Drug Resistance, 2013, 19, 355-361.	2.0	45
129	Improvement in Growth after Two Years of Growth Hormone Therapy in Very Young Children Born Small for Gestational Age and without Spontaneous Catch-Up Growth: Results of a Multicenter, Controlled, Randomized, Open Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3095-3101.	3.6	44
130	Evolution of the Pseudomonas aeruginosa Aminoglycoside Mutational Resistome In Vitro and in the Cystic Fibrosis Setting. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	44
131	Minimum information about a biofilm experiment (MIABiE): standards for reporting experiments and data on sessile microbial communities living at interfaces. Pathogens and Disease, 2014, 70, 250-256.	2.0	43
132	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum Î²-Lactamaseâ€“Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623.	5.8	43
133	Differential Â-lactam resistance response driven by ampD or dacB (PBP4) inactivation in genetically diverse Pseudomonas aeruginosa strains. Journal of Antimicrobial Chemotherapy, 2010, 65, 1540-1542.	3.0	42
134	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1672-1680.	3.0	41
135	Identifying and exploiting genes that potentiate the evolution of antibiotic resistance. Nature Ecology and Evolution, 2018, 2, 1033-1039.	7.8	41
136	Meropenem Penetration into Epithelial Lining Fluid in Mice and Humans and Delineation of Exposure Targets. Antimicrobial Agents and Chemotherapy, 2011, 55, 3406-3412.	3.2	40
137	A trade-off between oxidative stress resistance and DNA repair plays a role in the evolution of elevated mutation rates in bacteria. Proceedings of the Royal Society B: Biological Sciences, 2013, 280, 20130007.	2.6	40
138	<i>In vivo</i>evolution of resistance of<i>Pseudomonas aeruginosa</i>strains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure. Journal of Antimicrobial Chemotherapy, 2015, 70, 3004-3013.	3.0	39
139	Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the Caenorhabditis elegansPseudomonas aeruginosa Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	39
140	Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting. Clinical Microbiology and Infection, 2005, 11, 887-892.	6.0	38
141	Molecular mechanisms driving the<i>in vivo</i>development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR<i>Pseudomonas aeruginosa</i>infections. Journal of Antimicrobial Chemotherapy, 2021, 76, 91-100.	3.0	38
142	Assessing the Emergence of Resistance: The Absence of Biological Cost In Vivo May Compromise Fosfomycin Treatments for P. aeruginosa Infections. PLoS ONE, 2010, 5, e10193.	2.5	37
143	Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1. Journal of Antimicrobial Chemotherapy, 2010, 65, 1399-1404.	3.0	37
144	Selective trihydroxyazepane NagZ inhibitors increase sensitivity of Pseudomonas aeruginosa to Î²-lactams. Chemical Communications, 2013, 49, 10983.	4.1	36

#	ARTICLE	IF	CITATIONS
145	Molecular identification of aminoglycoside-modifying enzymes in clinical isolates of Escherichia coli resistant to amoxicillin/clavulanic acid isolated in Spain. International Journal of Antimicrobial Agents, 2015, 46, 157-163.	2.5	36
146	Interplay between Peptidoglycan Biology and Virulence in Gram-Negative Pathogens. Microbiology and Molecular Biology Reviews, 2018, 82, .	6.6	36
147	Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum Î²-lactamase-producing Enterobacteriaceae. International Journal of Antimicrobial Agents, 2018, 52, 577-585.	2.5	36
148	Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis. Clinical Microbiology and Infection, 2021, 27, 1631-1637.	6.0	36
149	Nosocomial spread of Pseudomonas aeruginosa producing the metallo-Î²-lactamase VIM-2 in a Spanish hospital: clinical and epidemiological implications. Clinical Microbiology and Infection, 2007, 13, 1026-1029.	6.0	35
150	Nosocomial Outbreak of a Non-Cefepime-Susceptible Ceftazidime-Susceptible Pseudomonas aeruginosa Strain Overexpressing MexXY-OprM and Producing an Integron-Borne PSE-1 ÃŸ-Lactamase. Journal of Clinical Microbiology, 2009, 47, 2381-2387.	3.9	35
151	Consenso espaÃ±ol para la prevenciÃ³n y el tratamiento de la infecciÃ³n bronquial por Pseudomonas aeruginosa en el paciente con fibrosis quÃstica. Archivos De Bronconeumologia, 2015, 51, 140-150.	0.8	35
152	<i>In Vitro</i> and <i>In Vivo</i> Activities of Î²-Lactams in Combination with the Novel Î²-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-Î²-Lactamase-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	35
153	The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant. Nature Genetics, 2021, 53, 1405-1414.	21.4	35
154	Influence of High Mutation Rates on the Mechanisms and Dynamics of In Vitro and In Vivo Resistance Development to Single or Combined Antipseudomonal Agents. Antimicrobial Agents and Chemotherapy, 2007, 51, 2574-2581.	3.2	34
155	A randomized trial of intravenous glutamine supplementation in trauma ICU patients. Intensive Care Medicine, 2014, 40, 539-547.	8.2	33
156	Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study. International Journal of Antimicrobial Agents, 2020, 55, 105847.	2.5	33
157	THE EFFECT OF ELEVATED MUTATION RATES ON THE EVOLUTION OF COOPERATION AND VIRULENCE OF<i>PSEUDOMONAS AERUGINOSA</i>. Evolution; International Journal of Organic Evolution, 2010, 64, 515-521.	2.3	32
158	Targeting the permeability barrier and peptidoglycan recycling pathways to disarm Pseudomonas aeruginosa against the innate immune system. PLoS ONE, 2017, 12, e0181932.	2.5	32
159	Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	31
160	Hypermutation in Burkholderia cepacia complex is mediated by DNA mismatch repair inactivation and is highly prevalent in cystic fibrosis chronic respiratory infection. International Journal of Medical Microbiology, 2014, 304, 1182-1191.	3.6	30
161	Genotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains. BMC Genomics, 2015, 16, 883.	2.8	30
162	Impact of multidrug resistance on the pathogenicity of Pseudomonas aeruginosa: in vitro and in vivo studies. International Journal of Antimicrobial Agents, 2016, 47, 368-374.	2.5	30

#	ARTICLE	IF	CITATIONS
163	Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	30
164	Role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo-Â-lactamases. Journal of Antimicrobial Chemotherapy, 2010, 65, 1950-1954.	3.0	29
165	Emergence of Resistance to Novel Cephalosporinâ€“Î²-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump. Antimicrobial Agents and Chemotherapy, 2021, 65, e0008921.	3.2	29
166	Optical Music Recognition for Scores Written in White Mensural Notation. Eurasip Journal on Image and Video Processing, 2009, 2009, 1-23.	2.6	28
167	Selection of AmpC Î²-Lactamase Variants and Metallo-Î²-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0206721.	3.2	28
168	Ampicillin-Sulbactam and Amoxicillin-Clavulanate Susceptibility Testing of <i>Escherichia coli</i> Isolates with Different Î²-Lactam Resistance Phenotypes. Antimicrobial Agents and Chemotherapy, 1999, 43, 862-867.	3.2	27
169	First detection in Europe of the metallo-Î²-lactamase IMP-15 in clinical strains of Pseudomonas putida and Pseudomonas aeruginosa. Clinical Microbiology and Infection, 2013, 19, E424-E427.	6.0	27
170	Deciphering Î²-lactamase-independent Î²-lactam resistance evolution trajectories in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2018, 73, 3322-3331.	3.0	27
171	Adding Insult to Injury: Mechanistic Basis for How AmpC Mutations Allow Pseudomonas aeruginosa To Accelerate Cephalosporin Hydrolysis and Evade Avibactam. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	27
172	Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2. International Journal of Antimicrobial Agents, 2020, 56, 106026.	2.5	27
173	Characterization of a novel Zn2+-dependent intrinsic imipenemase from Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2014, 69, 2972-2978.	3.0	26
174	Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable<i>Pseudomonas aeruginosa</i>. Journal of Antimicrobial Chemotherapy, 2016, 71, 3157-3167.	3.0	26
175	Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	26
176	Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection. Journal of Antimicrobial Chemotherapy, 2020, 75, 3209-3217.	3.0	26
177	Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2020, 75, 1474-1478.	3.0	26
178	<i>Pseudomonas aeruginosa</i>: a clinical and genomics update. FEMS Microbiology Reviews, 2021, 45, .	8.6	26
179	Detection of the Novel Extended-Spectrum Î²-Lactamase OXA-161 from a Plasmid-Located Integron in<i>Pseudomonas aeruginosa</i>Clinical Isolates from Spain. Antimicrobial Agents and Chemotherapy, 2009, 53, 5288-5290.	3.2	25
180	Molecular epidemiology and resistance profiles of Clostridium difficile in a tertiary care hospital in Spain. International Journal of Medical Microbiology, 2013, 303, 128-133.	3.6	25

#	Article	IF	Citations
181	Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections. Antimicrobial Agents and Chemotherapy, 2016, 60, 2912-2922.	3.2	25
182	Synergistic activity of fosfomycin, Î²-lactams and peptidoglycan recycling inhibition against<i>Pseudomonas aeruginosa</i>. Journal of Antimicrobial Chemotherapy, 2017, 72, 448-454.	3.0	25
183	Escherichia coli producing SHV-type extended-spectrum Â-lactamase is a significant cause of community-acquired infection. Journal of Antimicrobial Chemotherapy, 2009, 63, 781-784.	3.0	24
184	MÃ©todos microbiolÃ³gicos para la vigilancia del estado de portador de bacterias multirresistentes. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 667-675.	0.5	24
185	Phenylboronic Acid Derivatives as Validated Leads Active in Clinical Strains Overexpressing KPCâ€2: A Step against Bacterial Resistance. ChemMedChem, 2018, 13, 713-724.	3.2	24
186	Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study. Clinical Infectious Diseases, 2020, 70, 2270-2280.	5.8	24
187	In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2020, 75, 2508-2515.	3.0	24
188	First Report of an OXA-23 Carbapenemase-Producing Acinetobacter baumannii Clinical Isolate Related to Tn2006in Spain. Antimicrobial Agents and Chemotherapy, 2013, 57, 589-591.	3.2	23
189	Inhibitor-Resistant TEM- and OXA-1-Producing Escherichia coli Isolates Resistant to Amoxicillin-Clavulanate Are More Clonal and Possess Lower Virulence Gene Content than Susceptible Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2014, 58, 3874-3881.	3.2	23
190	Overexpression of MexCD-OprJ Reduces Pseudomonas aeruginosa Virulence by Increasing Its Susceptibility to Complement-Mediated Killing. Antimicrobial Agents and Chemotherapy, 2014, 58, 2426-2429.	3.2	23
191	Susceptibility profiles and resistance genomics of <i>Pseudomonas aeruginosa</i> isolates from European ICUs participating in the ASPIRE-ICU trial. Journal of Antimicrobial Chemotherapy, 2022, 77, 1862-1872.	3.0	23
192	Molecular epidemiology of methicillin-resistant Staphylococcus aureus in Majorcan hospitals: high prevalence of the epidemic clone EMRSA-15. Clinical Microbiology and Infection, 2007, 13, 599-605.	6.0	22
193	Nontypable Haemophilus influenzae Displays a Prevalent Surface Structure Molecular Pattern in Clinical Isolates. PLoS ONE, 2011, 6, e21133.	2.5	22
194	Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	22
195	Higher MICs (&gt;2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam. Open Forum Infectious Diseases, 2019, 6, ofz416.	0.9	22
196	Nosocomial dissemination of VIM-2-producing ST235 Pseudomonas aeruginosa in Lithuania. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 195-200.	2.9	21
197	Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa Sequence Type 175 in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21
198	Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21

#	ARTICLE	IF	CITATIONS
199	Social Behavior of Antibiotic Resistant Mutants Within Pseudomonas aeruginosa Biofilm Communities. Frontiers in Microbiology, 2019, 10, 570.	3.5	21
200	Challenges for accurate susceptibility testing, detection and interpretation of Â-lactam resistance phenotypes in Pseudomonas aeruginosa: results from a Spanish multicentre study. Journal of Antimicrobial Chemotherapy, 2013, 68, 619-630.	3.0	20
201	Antibiotic resistance and population structure of cystic fibrosis Pseudomonas aeruginosa isolates from a Spanish multi-centre study. International Journal of Antimicrobial Agents, 2017, 50, 334-341.	2.5	20
202	Long-term Persistence of an Extensively Drug-Resistant Subclade of Globally Distributed Pseudomonas aeruginosa Clonal Complex 446 in an Academic Medical Center. Clinical Infectious Diseases, 2020, 71, 1524-1531.	5.8	20
203	CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3. Frontiers in Microbiology, 0, 13, .	3.5	20
204	Mobile Genetic Elements Related to the Diffusion of Plasmid-Mediated AmpC Î²-Lactamases or Carbapenemases from Enterobacteriaceae: Findings from a Multicenter Study in Spain. Antimicrobial Agents and Chemotherapy, 2015, 59, 5260-5266.	3.2	19
205	Susceptibility to R-pyocins of Pseudomonas aeruginosa clinical isolates from cystic fibrosis patients. Journal of Antimicrobial Chemotherapy, 2018, 73, 2770-2776.	3.0	19
206	Combination versus monotherapy as definitive treatment for <i>Pseudomonas aeruginosa</i> bacteraemia: a multicentre retrospective observational cohort study. Journal of Antimicrobial Chemotherapy, 2021, 76, 2172-2181.	3.0	19
207	Performance of the VITEK2 system for identification and susceptibility testing of routine Enterobacteriaceae clinical isolates. International Journal of Antimicrobial Agents, 2001, 17, 371-376.	2.5	18
208	Development of antibiotic resistance and up-regulation of the antimutator gene pfpI in mutator Pseudomonas aeruginosa due to inactivation of two DNA oxidative repair genes (mutY, mutM). FEMS Microbiology Letters, 2011, 324, 28-37.	1.8	18
209	Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey. Journal of Antimicrobial Chemotherapy, 2019, 74, 3217-3220.	3.0	18
210	In Vivo Validation of Peptidoglycan Recycling as a Target to Disable AmpC-Mediated Resistance and Reduce Virulence Enhancing the Cell-Wallâ€“Targeting Immunity. Journal of Infectious Diseases, 2019, 220, 1729-1737.	4.0	18
211	Temperate Bacteriophages (Prophages) in Pseudomonas aeruginosa Isolates Belonging to the International Cystic Fibrosis Clone (CC274). Frontiers in Microbiology, 2020, 11, 556706.	3.5	18
212	Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates. Microbiology Spectrum, 2021, 9, e0058521.	3.0	18
213	Validation of the VITEK2 and the advance expert system with a collection of enterobacteriaceae harboring extended spectrum or inhibitor resistant Î²-lactamases. Diagnostic Microbiology and Infectious Disease, 2001, 41, 65-70.	1.8	17
214	Spanish Consensus on the Prevention and Treatment of Pseudomonas aeruginosa Bronchial Infections in Cystic Fibrosis Patients. Archivos De Bronconeumologia, 2015, 51, 140-150.	0.8	17
215	Surfactant Protein A Recognizes Outer Membrane Protein OprH on<i>Pseudomonas aeruginosa</i>Isolates From Individuals With Chronic Infection. Journal of Infectious Diseases, 2016, 214, 1449-1455.	4.0	17
216	O-antigen serotyping and MALDI-TOF, potentially useful tools for optimizing semi-empiric antipseudomonal treatments through the early detection of high-risk clones. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 541-544.	2.9	17

#	Article	IF	Citations
217	Rapid Detection of <i>Pseudomonas aeruginosa</i> Biofilms via Enzymatic Liquefaction of Respiratory Samples. ACS Sensors, 2020, 5, 3956-3963.	7.8	17
218	MICROSATELLITE MARKERS IN THE INDIRECT ANALYSIS OF THE STEROID 21-HYDROXYLASE GENE. Prenatal Diagnosis, 1997, 17, 429-434.	2.3	16
219	Epidemiological relatedness of methicillin-resistant Staphylococcus aureus from a tertiary hospital and a geriatric institution in Spain. Clinical Microbiology and Infection, 2004, 10, 339-342.	6.0	16
220	<i>N</i>-Acetylcysteine Selectively Antagonizes the Activity of Imipenem in Pseudomonas aeruginosa by an OprD-Mediated Mechanism. Antimicrobial Agents and Chemotherapy, 2015, 59, 3246-3251.	3.2	16
221	Bronchopulmonary infectionâ€“colonization patterns in Spanish cystic fibrosis patients: Results from a national multicenter study. Journal of Cystic Fibrosis, 2016, 15, 357-365.	0.7	16
222	Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones. Journal of Global Antimicrobial Resistance, 2019, 18, 37-44.	2.2	16
223	Antibiotic pressure compensates the biological cost associated with Pseudomonas aeruginosa hypermutable phenotypes in vitro and in a murine model of chronic airways infection. Journal of Antimicrobial Chemotherapy, 2012, 67, 962-969.	3.0	15
224	Unusual Diversity of Acquired Î²-lactamases in Multidrug-ResistantPseudomonas aeruginosaIsolates in a Mexican Hospital. Microbial Drug Resistance, 2012, 18, 471-478.	2.0	15
225	Four Decades of Î²-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis. Clinical Pharmacokinetics, 2019, 58, 143-156.	3.5	15
226	Pathogenic characteristics of Pseudomonas aeruginosa bacteraemia isolates in a high-endemicity setting for ST175 and ST235 high-risk clones. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 671-678.	2.9	15
227	Breakpoints for carbapenemase-producing Enterobacteriaceae: Is the problem solved?. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2014, 32, 33-40.	0.5	14
228	Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in<i>Pseudomonas aeruginosa</i>isolates recovered from ICU patients in Spain and Portugal depicted by WGS. Journal of Antimicrobial Chemotherapy, 2021, 76, 370-379.	3.0	14
229	<i>In Vivo</i> Evolution of GES Î²-Lactamases Driven by Ceftazidime/Avibactam Treatment of Pseudomonas aeruginosa Infections. Antimicrobial Agents and Chemotherapy, 2021, 65, e0098621.	3.2	14
230	Platelet-Rich Plasma in a Patient with Cerebral Palsy. American Journal of Case Reports, 2015, 16, 469-472.	0.8	14
231	Comparative analysis of <i>in vitro</i> dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in <i>Pseudomonas aeruginosa</i> XDR high-risk clones. Journal of Antimicrobial Chemotherapy, 2022, 77, 957-968.	3.0	14
232	Epidemiological and Clinical Complexity of Amoxicillin-Clavulanate-Resistant Escherichia coli. Journal of Clinical Microbiology, 2013, 51, 2414-2417.	3.9	13
233	Activity of ceftazidimeâ€“avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 499-504.	0.5	13
234	Characterization of AmpC Î²-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 474-478.	0.5	13

#	Article	IF	Citations
235	TEM-71, a Novel Plasmid-Encoded, Extended-Spectrum Î²-Lactamase Produced by a Clinical Isolate of Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2002, 46, 2000-2003.	3.2	12
236	Chronic Respiratory Infections by Mucoid Carbapenemase-Producing <i>Pseudomonas aeruginosa</i> Strains, a New Potential Public Health Problem. Antimicrobial Agents and Chemotherapy, 2008, 52, 2285-2286.	3.2	12
237	Characterization of a Novel IMP-28 Metallo-Î²-Lactamase from a Spanish Klebsiella oxytoca Clinical Isolate. Antimicrobial Agents and Chemotherapy, 2012, 56, 4540-4543.	3.2	12
238	Understanding the acute inflammatory response to Pseudomonas aeruginosa infection: differences between susceptible and multidrug-resistant strains in a mouse peritonitis model. International Journal of Antimicrobial Agents, 2017, 49, 198-203.	2.5	12
239	Comparative Analysis of Peptidoglycans From Pseudomonas aeruginosa Isolates Recovered From Chronic and Acute Infections. Frontiers in Microbiology, 2019, 10, 1868.	3.5	12
240	A Genome-Based Model to Predict the Virulence of Pseudomonas aeruginosa Isolates. MBio, 2020, 11, .	4.1	12
241	Carrier detection and prenatal diagnosis of congenital adrenal hyperplasia must identify â€˜apparently mildâ€™ CYP21A2 alleles which associate neonatal saltâ€wasting disease. Prenatal Diagnosis, 2010, 30, 758-763.	2.3	11
242	Comparison of Local Features from Two Spanish Hospitals Reveals Common and Specific Traits at Multiple Levels of the Molecular Epidemiology of Metallo-Î²-Lactamase-Producing Pseudomonas spp. Antimicrobial Agents and Chemotherapy, 2014, 58, 2454-2458.	3.2	11
243	Rates of faecal colonization by carbapenemase-producing Enterobacteriaceae among patients admitted to ICUs in Spain: Table 1.. Journal of Antimicrobial Chemotherapy, 2015, 70, 2916-2918.	3.0	11
244	Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	11
245	Del CLSI al EUCAST, una transiciÃ³n necesaria en los laboratorios espaÃ±oles. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 79-83.	0.5	11
246	Weighting the impact of virulence on the outcome of Pseudomonas aeruginosa bloodstream infections. Clinical Microbiology and Infection, 2020, 26, 351-357.	6.0	11
247	Mobile origami immunosensors for the rapid detection of urinary tract infections. Analyst, The, 2020, 145, 7916-7921.	3.5	11
248	Nosocomial outbreak linked to a flexible gastrointestinal endoscope contaminated with an amikacin-resistant ST17 clone of Pseudomonas aeruginosa. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1837-1844.	2.9	11
249	<i>In vitro</i>evolution of cefepime/zidebactam (WCK 5222) resistance in<i>Pseudomonas aeruginosa</i>: dynamics, mechanisms, fitness trade-off and impact on<i>in vivo</i>efficacy. Journal of Antimicrobial Chemotherapy, 2021, 76, 2546-2557.	3.0	11
250	Evolution of<i>Pseudomonas aeruginosa</i>Pathogenicity: From Acute to Chronic Infections. , 0, , 433-444.		10
251	Profiling the susceptibility of Pseudomonas aeruginosa strains from acute and chronic infections to cell-wall-targeting immune proteins. Scientific Reports, 2019, 9, 3575.	3.3	10
252	Emergence of Resistance to Novel Î²-Lactamâ€"Î²-Lactamase Inhibitor Combinations Due to Horizontally Acquired AmpC (FOX-4) in <i>Pseudomonas aeruginosa</i> Sequence Type 308. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	10

#	Article	IF	Citations
253	Bedside Detection of Carbapenemase-Producing Pathogens with Plasmonic Nanosensors. Sensors and Actuators B: Chemical, 2021, 329, 129059.	7.8	10
254	6-Halopyridylmethylidene Penicillin-Based Sulfones Efficiently Inactivate the Natural Resistance of <i>Pseudomonas aeruginosa</i> to Î²-Lactam Antibiotics. Journal of Medicinal Chemistry, 2021, 64, 6310-6328.	6.4	10
255	Pneumococcal psoas abscess: report of two cases. Clinical Microbiology and Infection, 2000, 6, 168-169.	6.0	9
256	Draft Genome Sequence of VIM-2-Producing Multidrug-Resistant Pseudomonas aeruginosa ST175, an Epidemic High-Risk Clone. Genome Announcements, 2013, 1, e0011213.	0.8	9
257	Therapeutic Efficacy of LN-1-255 in Combination with Imipenem in Severe Infection Caused by Carbapenem-Resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	9
258	Increased Susceptibility to Colistin in Hypermutable <i>Pseudomonas aeruginosa</i> Strains from Chronic Respiratory Infections. Antimicrobial Agents and Chemotherapy, 2007, 51, 4531-4532.	3.2	8
259	Expression of Toll-Like Receptors 2 and 4 is Upregulated During Hospital Admission in Traumatic Patients. Annals of Surgery, 2010, 251, 521-527.	4.2	8
260	Characterization of the New AmpC Î²-Lactamase FOX-8 Reveals a Single Mutation, Phe313Leu, Located in the R2 Loop That Affects Ceftazidime Hydrolysis. Antimicrobial Agents and Chemotherapy, 2013, 57, 5158-5161.	3.2	8
261	Microbiological diagnostic procedures for respiratory cystic fibrosis samples in Spain: towards standard of care practices. BMC Microbiology, 2014, 14, 335.	3.3	8
262	EpidemiologÃa y mecanismos de resistencia a carbapenemas en Pseudomonas aeruginosa : papel de los clones de alto riesgo en la multirresistencia. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 137-138.	0.5	8
263	Insights into the evolution of the mutational resistome of <i>Pseudomonas aeruginosa</i> in cystic fibrosis. Future Microbiology, 2017, 12, 1445-1448.	2.0	8
264	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. International Journal of Antimicrobial Agents, 2017, 50, 664-672.	2.5	8
265	Microbiological methods for surveillance of carrier status of multiresistant bacteria. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2017, 35, 667-675.	0.3	8
266	Prevalencia en EspaÃ±a de mecanismos de resistencia a quinolonas en enterobacterias productoras de betalactamasas de clase C adquiridas y/o carbapenemasas. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 487-492.	0.5	8
267	Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an <i>In Vitro</i> Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	8
268	Immunodetection of Lung IgG and IgM Antibodies against SARS-CoV-2 via Enzymatic Liquefaction of Respiratory Samples from COVID-19 Patients. Analytical Chemistry, 2021, 93, 5259-5266.	6.5	8
269	Recommendations for antibiotic selection for severe nosocomial infections. Revista Espanola De Quimioterapia, 2021, 34, 511-524.	1.3	8
270	Impact of Peptidoglycan Recycling Blockade and Expression of Horizontally Acquired Î²-Lactamases on Pseudomonas aeruginosa Virulence. Microbiology Spectrum, 2022, 10, e0201921.	3.0	8

#	ARTICLE	IF	CITATIONS
271	Rapid Identification and Classification of Pathogens That Produce Carbapenemases and Cephalosporinases with a Colorimetric Paper-Based Multisensor. Analytical Chemistry, 2022, 94, 9442-9449.	6.5	8
272	Genetic and Kinetic Characterization of the Novel AmpC Î²-Lactamases DHA-6 and DHA-7. Antimicrobial Agents and Chemotherapy, 2014, 58, 6544-6549.	3.2	7
273	Antimicrobial stewardship in Spain: Programs for Optimizing the use of Antibiotics (PROA) in Spanish hospitals. Germs, 2018, 8, 109-112.	1.3	7
274	WGS characterization of MDR Enterobacterales with different ceftolozane/tazobactam susceptibility profiles during the SUPERIOR surveillance study in Spain. JAC-Antimicrobial Resistance, 2020, 2, dlaa084.	2.1	7
275	Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable Pseudomonas aeruginosa in a Dynamic Biofilm Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	7
276	Molecular Basis of AmpC Î²-Lactamase Induction by Avibactam in Pseudomonas aeruginosa: PBP Occupancy, Live Cell Binding Dynamics and Impact on Resistant Clinical Isolates Harboring PDC-X Variants. International Journal of Molecular Sciences, 2021, 22, 3051.	4.1	7
277	Predictive Immunological, Virological, and Routine Laboratory Markers for Critical COVID-19 on Admission. Canadian Journal of Infectious Diseases and Medical Microbiology, 2021, 2021, 1-8.	1.9	7
278	Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model. Journal of Global Antimicrobial Resistance, 2021, 26, 55-63.	2.2	7
279	Molecular Analysis of the Contribution of Alkaline Protease A and Elastase B to the Virulence of Pseudomonas aeruginosa Bloodstream Infections. Frontiers in Cellular and Infection Microbiology, 2021, 11, 816356.	3.9	7
280	<i>In vivo</i> translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against <i>Pseudomonas aeruginosa</i>. Journal of Antimicrobial Chemotherapy, 2022, 77, 2803-2808.	3.0	7
281	Prevalence of extended-spectrum Î²-lactamases in group-1 Î²-lactamase-producing isolates. Clinical Microbiology and Infection, 2001, 7, 278-282.	6.0	6
282	Hypermutation in natural bacterial populations: consequences for medical microbiology. Reviews in Medical Microbiology, 2005, 16, 25-32.	0.9	6
283	Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2020, 38, 182-187.	0.5	6
284	Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model. Scientific Reports, 2021, 11, 22178.	3.3	6
285	Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective Study. Infectious Diseases and Therapy, 0, , .	4.0	6
286	Antimicrobial stewardship programs: A public health priority in Spain. The SEIMC-REIPI initiative. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 1-2.	0.5	5
287	Draft Genome Sequence of the Quorum-Sensing and Biofilm-Producing Pseudomonas aeruginosa Strain Pae221, Belonging to the Epidemic High-Risk Clone Sequence Type 274. Genome Announcements, 2015, 3, .	0.8	5
288	Epidemiology and carbapenem resistance mechanisms in Pseudomonas aeruginosa : Role of high-risk clones in multidrug resistance. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2017, 35, 137-138.	0.3	5

#	ARTICLE	IF	CITATIONS
289	Activity of mammalian peptidoglycan-targeting immunity against Pseudomonas aeruginosa. Journal of Medical Microbiology, 2020, 69, 492-504.	1.8	5
290	Pseudomonas aeruginosa Susceptibility in Spain: Antimicrobial Activity and Resistance Suppression Evaluation by PK/PD Analysis. Pharmaceutics, 2021, 13, 1899.	4.5	5
291	Mammals' humoral immune proteins and peptides targeting the bacterial envelope: from natural protection to therapeutic applications against multidrugâ€·resistant <scp>Gram</scp>â€·negatives. Biological Reviews, 2022, 97, 1005-1037.	10.4	5
292	<i>In Vivo</i> Selection of Moxifloxacin-Resistant Clostridium difficile. Antimicrobial Agents and Chemotherapy, 2012, 56, 2788-2789.	3.2	4
293	Draft Genome Sequence of Colistin-Only-Susceptible Pseudomonas aeruginosa Strain ST235, a Hypervirulent High-Risk Clone in Spain. Genome Announcements, 2014, 2, .	0.8	4
294	Clinical relevance of Pseudomonas aeruginosa hypermutation in cystic fibrosis chronic respiratory infection. Journal of Cystic Fibrosis, 2015, 14, e1-e2.	0.7	4
295	Prevalence of quinolone resistance mechanisms in Enterobacteriaceae producing acquired AmpC Î²-lactamases and/or carbapenemases in Spain. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2017, 35, 485-490.	0.3	4
296	Increased Antimicrobial Resistance in a Novel CMY-54 AmpC-Type Enzyme with a GluLeu^{217â€“218} Insertion in the Î©-Loop. Microbial Drug Resistance, 2018, 24, 527-533.	2.0	4
297	Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable Pseudomonas Aeruginosa Strains via Mechanism-Based Modelling. Pharmaceutics, 2019, 11, 470.	4.5	4
298	Emergence of high-level and stable metronidazole resistance in Clostridioides difficile. International Journal of Antimicrobial Agents, 2020, 55, 105830.	2.5	4
299	Metagenomics Analysis Reveals an Extraordinary Inner Bacterial Diversity in Anisakids (Nematoda:) Tj ETQq1 1 0.784314 rgBT /Overlock	3.6	4
300	Validation of MALDI-TOF for the early detection of the ST175 high-risk clone of Pseudomonas aeruginosa in clinical isolates belonging to a Spanish nationwide multicenter study. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2021, 39, 279-282.	0.5	4
301	A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?. Infectious Diseases and Therapy, 2021, 10, 2677-2699.	4.0	4
302	Boosting the sensitivity of paper-based biosensors with polymeric water-soluble reservoirs. Sensors and Actuators B: Chemical, 2022, 354, 131214.	7.8	4
303	Multicenter Performance Evaluation of MALDI-TOF MS for Rapid Detection of Carbapenemase Activity in Enterobacterales: The Future of Networking Data Analysis With Online Software. Frontiers in Microbiology, 2021, 12, 789731.	3.5	4
304	Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling. Antimicrobial Agents and Chemotherapy, 2022, 66, aac0220321.	3.2	4
305	VIM-47, a New Variant of the Autochthonous Metallo-Î²-Lactamase VIM-13 from the Balearic Islands in Spain. Antimicrobial Agents and Chemotherapy, 2016, 60, 3251-3252.	3.2	3
306	Use of Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry Analysis of Serum Peptidome to Classify and Predict Coronavirus Disease 2019 Severity. Open Forum Infectious Diseases, 2021, 8, ofab222.	0.9	3

#	Article	IF	Citations
307	A Genomic Snapshot of the SARS-CoV-2 Pandemic in the Balearic Islands. Frontiers in Microbiology, 2021, 12, 803827.	3.5	3
308	From CLSI to EUCAST, a necessary step in Spanish laboratories. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2020, 38, 79-83.	0.3	2
309	Optimized detection of lung IL-6 <i>via</i> enzymatic liquefaction of low respiratory tract samples: application for managing ventilated patients. Analyst, The, 2021, 146, 6537-6546.	3.5	2
310	Validation of MALDI-TOF for the early detection of the ST175 high-risk clone of Pseudomonas aeruginosa in clinical isolates belonging to a Spanish nationwide multicenter study. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2021, 39, 279-282.	0.3	2
311	Whole-genome sequence-guided PCR for the rapid identification of the<i>Pseudomonas aeruginosa</i>ST175 high-risk clone directly from clinical samples. Journal of Antimicrobial Chemotherapy, 2021, 76, 945-949.	3.0	2
312	Comparison of Local Features from Two Spanish Hospitals Reveals Common and Specific Traits at Multiple Levels of the Molecular Epidemiology of Metallo-Î²-Lactamase-Producing Pseudomonas spp. Antimicrobial Agents and Chemotherapy, 2014, 58, 4992-4992.	3.2	1
313	Draft Genome Sequences of Four Pseudomonas aeruginosa Isolates Obtained from Patients with Chronic Obstructive Pulmonary Disease. Genome Announcements, 2017, 5, .	0.8	1
314	Characterization of the GO system of Pseudomonas aeruginosa. FEMS Microbiology Letters, 2002, 217, 31-35.	1.8	1
315	Characterization of AmpC Î²-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2020, 38, 474-478.	0.3	1
316	Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates. Microbiology Spectrum, 0, , .	3.0	1
317	P880 Single-step selection of double mutations leading to high antibiotic-resistance in hyper-mutable Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 2007, 29, S227-S228.	2.5	0
318	Activity of ceftazidimeâ€¢avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2017, 35, 497-502.	0.3	0
319	Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2020, 38, 182-187.	0.3	0
320	Inhaled corticosteroid use and its association with Pseudomonas aeruginosa infection in COPD. , 2021, , .		0
321	Role of inhaled corticosteroids on recurrent bronchial infection by potentially pathogenic bacteria in patients with COPD. , 2020, , .		0
322	Recommendations of the Spanish Antibiogram Committee (COESANT) for in vitro susceptibility testing of antimicrobial agents by disk diffusion. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2022, , .	0.5	0